MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Hatch, Harold ^a   Dolinski, Brian M ^a   Nguyen, Thi ^a   Harmonay, Lauren ^a   Al Assaad, Ali Samer ^a   Ayers, Mark ^a   Nebozhyn, Michael ^a   Loboda, Andrey ^a   Hirsch, Heather A ^a   Zhang, Theresa ^a   Shi, Bin ^a   Merkel, Carrie E ^a   Angagaw, Minilik H ^a   Wang, Yaolin ^a   Long, Brian J ^a   Lennon, Xianlu Q ^a   Miselis, Nathan ^a   Pucci, Vincenzo ^a   Monahan, James W ^a   Lee, Junghoon ^a   Kondic, Anna Georgieva ^a   Im, Eun Kyung ^a   Mauro, David ^a   Blanchard, Rebecca ^a   Gilliland, Gary ^a   Fawell, Stephen E ^a   Zawel, Leigh ^a   Schuller, Alwin G ^b   Strack, Peter ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; DINACICLIB; NAVITOCLAX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; DITERPENE; EPOXIDE; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; MESSENGER RNA; PHENANTHRENE DERIVATIVE; PROTEIN BCL X; PYRIDINIUM DERIVATIVE; SULFONAMIDE; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL LINE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MCL1 GENE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SINGLE DRUG DOSE; SOLID TUMOR; ANIMAL; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE DOSAGE; GENETICS; MALE; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DITERPENES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPOXY COMPOUNDS; FEMALE; GENE DOSAGE; HUMANS; MALE; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PHENANTHRENES; PYRIDINIUM COMPOUNDS; RNA, MESSENGER; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907841902     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108371     Document Type: Article

References (42)

1. Guha M (2012) Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov 11: 892-894. Available: http://www.ncbi.nlm.nih.gov/pubmed/23197022. Accessed 13 March 2014.
2. Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140: 3079-3093. Available: http://www.ncbi.nlm.nih.gov/pubmed/23861057. Accessed 23 February 2014.
3. Blachly JS, Byrd JC (2013) Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 54: 2133-2143. Available: http://www.ncbi.nlm.nih.gov/pubmed/23488658.
4. Bose P, Simmons GL, Grant S (2013) Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 22: 723-738. Available: http://www.ncbi.nlm.nih.gov/pubmed/23647051. Accessed 27 March 2014.
5. Mita M, Joy A a, Mita A, Sankhala K, Jou Y-M, et al. (2013) Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer. Clin Breast Cancer 2013.10.01: 1-8. Available: http://www.ncbi.nlm.nih.gov/pubmed/24393852. Accessed 13 March 2014.
6. Stephenson JJ, Nemunaitis J, Joy A a, Martin JC, Jou Y-M, et al. (2014) Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer 83: 219-223. Available: http://www.ncbi.nlm.nih.gov/pubmed/24388167. Accessed 27 February 2014.
7. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, et al. (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9: 2344-2353. Available: http://www.ncbi.nlm.nih.gov/pubmed/20663931. Accessed 26 February 2014.
8. Cai D, Latham VM, Zhang X, Shapiro GI (2006) Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66: 9270-9280. Available: http://www.ncbi.nlm.nih.gov/pubmed/16982772. Accessed 13 March 2014.
9. Oelgeschlager T (2002) Regulation of RNA Polymerase II Activity by CTD Phosphorylation and Cell Cycle Control. J Cell Physiol 169: 160-169. Available: http://www.ncbi.nlm.nih.gov/pubmed/11807820.
10. Fu W, Ma L, Chu B, Wang X, Bui MM, et al. (2011) The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 10: 1018-1027. Available: http://www.ncbi.nlm.nih.gov/pubmed/21490307.
11. Johnson AJ, Yeh Y, Smith LL, Wagner AJ, Hessler J, et al. (2012) The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 26: 2554-2557. Available: http://www.ncbi.nlm.nih.gov/pubmed/22791353.
12. Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106: 2513-2519. Available: http://www.ncbi.nlm.nih.gov/pubmed/15972445.
13. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, et al. (2005) A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53- dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105: 4484-4491. Available: http://www.ncbi.nlm.nih.gov/pubmed/15692065. Accessed 13 March 2014.
14. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, et al. (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113: 4637-4645. Available: http://www.ncbi.nlm.nih.gov/pubmed/19234140.
15. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, et al. (2011) Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12: 598-609. Available: http://www.ncbi.nlm.nih.gov/pubmed/21768779. Accessed 27 February 2014.
16. Desai BM, Villanueva J, Nguyen T-TK, Lioni M, Xiao M, et al. (2013) The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 8: e59588. Available: http://www.ncbi.nlm.nih.gov/pubmed/23527225. Accessed 27 February 2014.
17. Nguyen TK, Grant S (2014) Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- And 5-dependent mechanism. Mol Cancer Ther 13: 662-674. Available: http://www.ncbi.nlm.nih.gov/pubmed/24362465. Accessed 29 April 2014.
18. Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, et al. (2013) A firstin- human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11: 259. Available: http://www.ncbi.nlm.nih.gov/pubmed/24131779. Accessed 28 February 2014.
19. Hardwick JS, Yang Y, Zhang C, Shi B, Mcfall R, et al. (2005) Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling proliferation through gene expression profiling: 413-425. Available: http://www.ncbi.nlm.nih.gov/pubmed/15767550.
20. Shi B, Hardwick J, Connolly B, Mao X, McFall R, et al. (2010) Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model. J Histotechnol 33: 15-24. Available: http://www.maneyonline.com/doi/abs/10.1179/his.2010.33.1.15.
21. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-307. Available: http://www.ncbi.nlm.nih.gov/pubmed/22460905.
22. Lehár J, Zimmermann GR, Krueger AS, Molnar R a, Ledell JT, et al. (2007) Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3: 80. Available: http://www.ncbi.nlm.nih.gov/pubmed/17332758. Accessed 24 February 2014.
23. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, et al. (2012) Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21: 547-562. Available: http://www.ncbi.nlm.nih.gov/pubmed/22516262. Accessed 26 February 2014.
24. Graidist P, Phongdara A, Fujise K (2004) Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity. J Biol Chem 279: 40868-40875. Available: http://www.ncbi.nlm.nih.gov/pubmed/15262975. Accessed 13 March 2014.
25. Leuenroth SJ, Crews CM (2008) Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res 68: 5257-5266. Available: http://www.ncbi.nlm.nih.gov/pubmed/18593926.
26. Serizawa H, Mäkelä TP, Conaway JW, Conaway RC, Weinberg RA, et al. (1995) Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 374: 280-282. Available: http://www.ncbi.nlm.nih.gov/pubmed/7885450.
27. Hann SR, Eisenman RN (1984) Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 4: 2486-2497. Available: http://www.ncbi.nlm.nih.gov/pubmed/6513926.
28. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nuñez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13: 683-691. Available: http://www.ncbi.nlm.nih.gov/pubmed/8313913.
29. Kutuk O, Temel SG, Tolunay S, Basaga H (2010) Aven blocks DNA damageinduced apoptosis by stabilising Bcl-xL. Eur J Cancer 46: 2494-2505. Available: http://www.ncbi.nlm.nih.gov/pubmed/20619636.
30. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421- 3428. Available: http://www.ncbi.nlm.nih.gov/pubmed/18451170. Accessed 4 February 2014.
31. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268-3277. Available: http://www.ncbi.nlm.nih.gov/pubmed/18519752. Accessed 13 March 2014.
32. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy A V, et al. (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67: 1176-1183. Available: http://www.ncbi.nlm.nih.gov/pubmed/17283153. Accessed 13 March 2014.
33. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, et al. (2011) Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30: 1963-1968. Available: http://www.ncbi.nlm.nih.gov/pubmed/21132008. Accessed 13 March 2014.
34. Gutiérrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, et al. (1999) Bax Is Frequently Compromised in Burkitt's Lymphomas with Irreversible Resistance to Fas-induced Apoptosis Bax Is Frequently Compromised in Burkitt's Lymphomas with Irreversible Resistance to Fas-induced Apoptosis. Cancer Res 59: 696-703. Available: http://www.ncbi.nlm.nih.gov/pubmed/9973220.
35. Von Haefen C, Gillissen B, Hemmati PG, Wendt J, Güner D, et al. (2004) Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23: 8320-8332. Available: http://www.ncbi.nlm.nih.gov/pubmed/15467752. Accessed 13 March 2014.
36. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Slöetjes a W, et al. (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91: 2991-2997. Available: http://www.ncbi.nlm.nih.gov/pubmed/9531611.
37. Hussain A, Doucet JP, Gutiérrez M, Ahmad M, Al-Hussein K, et al. (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica 88: 165-175. Available: http://www.ncbi.nlm.nih.gov/pubmed/12604406.
38. Mpakou VE, Kontsioti F, Papageorgiou S, Spathis A, Kottaridi C, et al. (2013) Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation. Leuk Res 37: 175- 182. Available: http://www.ncbi.nlm.nih.gov/pubmed/23149070. Accessed 1 March 2014.
39. He M-F, Huang Y-H, Wu L-W, Ge W, Shaw P-C, et al. (2010) Triptolide functions as a potent angiogenesis inhibitor. Int J Cancer 126: 266-278. Available: http://www.ncbi.nlm.nih.gov/pubmed/19569053. Accessed 13 March 2014.
40. Adams KW, Cooper GM (2007) Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282: 6192-6200. Available: http://www.ncbi.nlm.nih.gov/pubmed/17200126.
41. Thomas LW, Lam C, Clark RE, White MRH, Spiller DG, et al. (2012) Serine 162, an essential residue for the mitochondrial localization, stability and antiapoptotic function of Mcl-1. PLoS One 7: e45088. Available: http://www.ncbi.nlm.nih.gov/pubmed/23024798. Accessed 6 February 2014.
42. Horiuchi D, Huskey NE, Kusdra L, Wohlbold L, Merrick K a, et al. (2012) Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci U S A 109: E1019-27. Available: http://www.ncbi.nlm.nih.gov/pubmed/22474407. Accessed 6 March 2014.